Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

BMC Med. 2013 Oct 17;11:220. doi: 10.1186/1741-7015-11-220.

2.

Criteria for the use of omics-based predictors in clinical trials.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564.

3.

Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Williams PM, Lively TG, Jessup JM, Conley BA.

Clin Cancer Res. 2012 Mar 15;18(6):1531-9. doi: 10.1158/1078-0432.CCR-11-2203.

4.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
5.

Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice.

Jessup JM, Lively TG, Taube SE.

Expert Rev Mol Diagn. 2005 May;5(3):271-3. No abstract available.

PMID:
15934805

Supplemental Content

Loading ...
Support Center